Semaglutide and Male Fertility: What GLP-1 Drugs Do to Testosterone and Sperm

Why Men on GLP-1 Drugs Are Asking About Fertility

When GLP-1 receptor agonists first came to market, the primary user demographic was women with type 2 diabetes. That has changed substantially. Prescriptions for semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) in men have accelerated rapidly as the drugs gained recognition for treating metabolic syndrome — a cluster of conditions including abdominal obesity, insulin resistance, hypertension, and dyslipidemia that affects roughly 35% of adult men in the United States.

For men in their reproductive years, metabolic syndrome frequently co-occurs with functional hypogonadism — low testosterone driven not by testicular or pituitary pathology but by excess adipose tissue and its hormonal consequences. As these men begin losing weight on GLP-1 drugs, many notice changes in energy, libido, and body composition that raise natural questions about what is happening to their reproductive hormones.

The Obesity-Testosterone Link: Understanding the Baseline Problem

To understand what semaglutide does to testosterone, you first need to understand what obesity does to it. The relationship between adipose tissue and male sex hormones is well-characterized and operates primarily through two mechanisms.

Aromatase Conversion

Adipose tissue — particularly visceral (intra-abdominal) fat — expresses the enzyme aromatase (CYP19A1) at high levels. Aromatase converts testosterone and androstenedione into estradiol and estrone. The more fat tissue a man carries, the more aromatase activity he has, and the more testosterone is converted to estrogen rather than remaining bioavailable as free or total testosterone.

This creates a self-reinforcing cycle: high estrogen from aromatization feeds back to the hypothalamus and pituitary to suppress gonadotropin-releasing hormone (GnRH) and luteinizing hormone (LH), which in turn reduces testicular testosterone production. Corona et al. documented this mechanism comprehensively, showing that obese men have significantly elevated estradiol-to-testosterone ratios compared to lean controls — independent of age.

SHBG Depression

Obesity and insulin resistance suppress hepatic production of sex hormone-binding globulin (SHBG), the protein that binds and transports testosterone in blood. Lower SHBG means less bound testosterone — but paradoxically, it also means more rapid clearance and metabolism of testosterone. Total testosterone measured on a standard lab panel may look low even when free testosterone fractions are relatively preserved, making SHBG context essential for interpreting any hormone panel in an overweight man.

What Semaglutide Studies Show: SELECT and Beyond

The most important large-scale semaglutide trial with cardiovascular endpoints — the SELECT trial (Semaglutide and Cardiovascular Outcomes in Adults with Overweight or Obesity) — enrolled over 17,000 participants with established cardiovascular disease but without diabetes. SELECT did not have reproductive hormone assessment as a primary endpoint and did not report granular testosterone data stratified by sex and baseline hormonal status. This is a genuine evidence gap.

What SELECT and the SCALE trials (Semaglutide Treatment Effect in People with Obesity) do show consistently is significant body weight reduction — averaging 12–17% of body weight over 68 weeks at maximum doses. The hormonal implications of that weight loss have been studied extensively in the context of bariatric surgery and dietary weight loss interventions, which provide the strongest proxy data available.

Sperm Quality and Obesity: The Baseline Problem for Fertility

Before examining what GLP-1 drugs do to sperm, it is worth establishing what obesity itself does — because this baseline matters enormously for interpreting any changes on treatment.

A landmark 2012 meta-analysis published in Obesity Reviews pooled data from 13,077 men across 30 studies and found that obese men (BMI >30) had significantly lower total sperm count, reduced motility, worse morphology scores, and higher rates of sperm DNA fragmentation compared to normal-weight controls. The effect size was clinically meaningful: obese men had approximately 1.5 times the odds of oligospermia (low sperm count) compared to lean men.

The mechanisms involve elevated scrotal temperature from adipose tissue surrounding the testes, oxidative stress from chronic systemic inflammation, hormonal disruption via aromatase, and potentially epigenetic modifications to sperm DNA. Weight loss — through any mechanism — has been shown in multiple studies to improve all four parameters, typically over a 3–6 month timeline that reflects sperm maturation cycles (spermatogenesis takes approximately 72 days from start to mature sperm).

The Net Hormonal Effect for Most Men: Usually Positive

For the typical male semaglutide user — an overweight or obese man with metabolic syndrome and functional hypogonadism — the net reproductive hormone effect of treatment is likely beneficial. Here is why:

Camacho et al. synthesized evidence across dietary, pharmacological, and surgical weight loss interventions and found that reducing body fat mass by approximately 10% was associated with a 30–50% rise in total testosterone, with free testosterone rising proportionally. The mechanism is straightforward: less adipose tissue means less aromatase activity, which means less testosterone-to-estrogen conversion and less estrogenic suppression of the hypothalamic-pituitary-gonadal (HPG) axis.

Men who achieve 15% body weight loss on semaglutide — which is achievable with consistent dosing at 2.4 mg/week — may reasonably expect testosterone levels to normalize if their hypogonadism was purely functional (obesity-driven) rather than primary or secondary hypogonadism from a structural cause.

The Caloric Restriction Caveat: Short-Term Hormonal Suppression

GLP-1 drugs work primarily by suppressing appetite, creating a sustained caloric deficit. During active caloric restriction — particularly in the first several months of treatment — a transient secondary effect can partially offset the testosterone gains from fat loss.

Significant caloric restriction signals energy scarcity to the hypothalamus, which can temporarily reduce GnRH pulse frequency. Reduced GnRH pulsatility means less LH and FSH secretion from the pituitary, and lower LH means reduced Leydig cell stimulation in the testes. This effect is well-documented in endurance athletes and in men following very low calorie diets (below ~1200–1400 kcal/day).

The important practical point: this suppression is typically modest and transient. As body fat decreases and the hormonal environment normalizes, hypothalamic function generally recovers. Men who crash-diet aggressively while on GLP-1 drugs — eating far below maintenance in addition to appetite suppression — face the greatest risk of transient hormonal suppression.

Nausea, Libido, and the Titration Period

One of the most commonly reported sexual health complaints from men on semaglutide during dose titration is reduced libido. This is almost certainly not a direct hormonal effect. Rather, it tracks directly with nausea — the most prevalent side effect during the titration phase (typically the first 12–20 weeks as doses escalate from 0.25 mg to 2.4 mg weekly).

Nausea is physiologically suppressive of sexual desire across all genders. The mechanism is straightforward: the autonomic nervous system state associated with nausea (parasympathetic dominance, vagal activation) is essentially incompatible with the sympathetic arousal state required for sexual interest and response. Men who report low libido during titration typically see it normalize once nausea resolves at a stable maintenance dose — usually by weeks 16–24.

This is worth distinguishing clearly from any sustained effect on hormonal libido drivers, because the two have very different clinical implications and trajectories.

What to Monitor: A Practical Hormone Panel

Men Actively Trying to Conceive: What the Data (and Gaps) Say

This is where intellectual honesty requires acknowledging a genuine evidence gap. No published randomized controlled trial has specifically examined semaglutide's effects on semen parameters or male fertility outcomes as a primary endpoint. The available data come from three sources:

• Weight loss intervention studies using dietary or surgical approaches — strongly consistent in showing sperm parameter improvement with significant weight loss, applicable by extrapolation to semaglutide-achieved weight loss
• Animal reproductive toxicology studies required by regulators before approval — these show no evidence of direct spermatotoxicity at therapeutic dose ranges in rodent models
• Pharmacovigilance data from post-market surveillance — no signal for male infertility or sperm abnormalities has been flagged in FAERS (FDA Adverse Event Reporting System) data as of mid-2026

The honest interpretation: the available evidence does not suggest semaglutide harms male fertility, and the weight loss it produces is likely net beneficial for sperm quality in overweight men. However, the absence of evidence is not the same as evidence of absence. Men who are actively trying to conceive and have concerns should discuss timing and monitoring with a urologist or reproductive endocrinologist.

Muscle Mass: The Underappreciated Risk for Men

GLP-1-mediated weight loss is not pure fat loss. Across multiple SCALE and SELECT trial analyses, roughly 25–40% of total weight lost was lean mass (muscle) rather than fat. This is biologically normal during rapid weight loss, but it carries specific implications for men who are also trying to maintain testosterone-supporting body composition.

Skeletal muscle is not merely a cosmetic concern in this context. Muscle mass is a significant driver of insulin sensitivity (which affects SHBG and free testosterone), basal metabolic rate (which determines how aggressive a caloric deficit becomes at a given intake level), and physical performance and anabolic hormone signaling. Men losing 20+ lbs on semaglutide without deliberate muscle preservation strategies may find their hormonal environment improves less than expected — or that libido and strength gains lag behind the scale improvements.

The two interventions with strong evidence for lean mass preservation during GLP-1 therapy are progressive resistance training (at least 3 sessions per week, compound movements at sufficient intensity to stimulate hypertrophy) and adequate dietary protein intake (current evidence supports 0.7–1.0 g per pound of body weight daily during weight loss in men who are resistance training).

Bottom Line: What Men on GLP-1 Drugs Should Know

The research picture, while incomplete in places, supports a broadly positive narrative for male reproductive health with one important nuance:

• Testosterone almost always rises with meaningful fat loss in men who started overweight with functional hypogonadism — the aromatase reduction from fat loss is the dominant hormonal effect
• Sperm quality improves with weight loss — this is one of the most consistent findings in male reproductive medicine, and semaglutide-achieved weight loss should produce comparable improvements to other interventions achieving similar magnitude of fat reduction
• Short-term suppression during aggressive caloric restriction can occur — most relevant during rapid early weight loss phases; monitor LH/FSH if concerned
• Nausea-related libido reduction is real but temporary — resolves with stable dosing in most men by week 16–24
• No direct spermatotoxicity signal exists in animal studies or pharmacovigilance data, but dedicated human RCT data on semen parameters are lacking
• Muscle mass preservation requires active intervention — resistance training and protein targeting are non-negotiable for men who want the full reproductive and metabolic benefit of GLP-1 therapy